Scanning Electron Microscopy Visualization of Methicillin-Resistant Staphylococcus aureus After Contact With Gatifloxacin With and Without Preservative

Abstract

Purpose:

To test a visual model by looking at the differences in effect of Zymar^® (gatifloxacin plus benzalkonium chloride [BAK]) when compared to gatifloxacin and a normal saline (NS) control upon a methicillin and gatifloxacin-resistant Staphylococcus aureus (MRSA) species.

Methods:

An ocular isolate of gatifloxacin-resistant (minimal inhibitory concentration >2 to 4 μg/mL) MRSA was grown to confluency. Chambered slides were prepared with bacterial culture smears, and then incubated with either gatifloxacin at the concentrations of 1 and 10 μg/mL, Zymar^® containing equivalent concentrations of gatifloxacin, or NS. Bacterial cultures were fixed after 10, 30, and 60 min. Fixed slides were coated in gold sputter for examination. Bacteria were visually evaluated with scanning electron microscopy (SEM) at 50,000×. Blinded review of SEM images compared structural changes and mitotic activity across samples.

Results:

MRSA exposed to 10 μg Zymar^® for 60 min showed significantly greater pleomorphism and cell wall surface changes when compared to gatifloxacin (P < 0.0001) and NS (P = 0.001), and significantly less mitotic activity than NS (P = 0.002).

Conclusion:

Using SEM, the topical formulation of gatifloxacin 0.3% (Zymar^®), which contains BAK, had greater antibacterial activity than did gatifloxacin alone in gatifloxacin and methicillin-resistant S. aureus, thereby illustrating potential advantages of the preservative in the commercial formulation. We further show that these effects can be visualized and quantified.

Get full access to this article

View all access options for this article.

References

Asbell

P.A

., Colby

K.A

., Deng

., et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am. J. Ophthalmol. 145:951–958, 2008.

Blondeau

J.M

., Borsos

., and Hesje

C.K

. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus. J. Chemother. 19:146–151, 2007.

Han

D.P

., Wisniewski

S.R

., Wilson

L.A

., et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am. J. Ophthalmol. 122:1–17, 1996.

Kowalski

R.P

., and Dhaliwal

D.K

. Ocular bacterial infections: current and future treatment options. Expert Rev. Anti Infect. Ther. 3:131–139, 2005.

Tazawa

., and Ooishi

. MRSA ocular infections. Nippon Rinsho. 50:1122–1126, 1992.

Shanmuganathan

V.A

., Armstrong

., Buller

., et al. External ocular infections due to methicillin-resistant Staphylococcus aureus (MRSA). Eye. 19:284–291, 2005.

Blomquist

P.H

. Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 104:322–345, 2006.

Cavuoto

., Zutshi

., Karp

C.L

., et al. Update on bacterial conjunctivitis in South Florida. Ophthalmology. 115:51–56, 2008.

Fridkin

S.K

., Hageman

J.C

., Morrison

., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352:1436–1444, 2005.

10.

Rutar

., Chambers

H.F

., Crawford

J.B

., et al. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus. Ophthalmology. 113:1455–1462, 2006.

11.

Solomon

., Donnenfeld

E.D

., Perry

H.D

., et al. Methicillin-resistant Staphylococcus aureus infectious keratitis following refractive surgery. Am. J. Ophthalmol. 143:629–634, 2007.

12.

Fiscella

R.G

., Lewis

C.C

., and Jensen

M.K

. Topical ophthalmic fourth-generation fluoroquinolones: appropriate use and cost considerations. Am. J. Health Syst. Pharm. 64:2069–2073, 2007.

13.

Mah

F.S

. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr. Opin. Ophthalmol. 15:316–320, 2004.

14.

Tepedino

M.E

., Heller

W.H

., Usner

D.W

., et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr. Med. Res. Opin. 25:1159–1169, 2009.

15.

Sanders

M.E

., Norcross

E.W

., Moore

Q.C

III , et al. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis. Cornea. 28:1055-1060, 2009.

16.

McDonald

M.B

., Protzko

E.E

., Brunner

L.S

., et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 116:1615–1623 e1, 2009.

17.

Haas

., Pillar

C.M

., Zurenko

G.E

., et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 53:3552–3560, 2009.

18.

Zhang

J.Z

., and Ward

K.W

. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. J. Antimicrob. Chemother. 61:111–116, 2008.

19.

Zymar [package insert]. Irvine, CA: Allergan, Inc ., 2004.

20.

Friedlaender

M.H

., Breshears

., Amoozgar

., et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv. Ther. 23:835–841, 2006.

21.

Olson

. Zymar as an ocular therapeutic agent. Int. Ophthalmol. Clin. 46:73–84, 2006.

22.

Kowalski

R.P

., Kowalski

B.R

., Romanowski

E.G

., et al. The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy. Am. J. Ophthalmol. 142:730–735, 2006.

23.

Romanowski

E.G

., Mah

F.S

., Kowalski

R.P

., et al. Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis. J. Ocul. Pharmacol. Ther. 24:380–384, 2008.

24.

Dantas

P.E

., Uesugui

., Nishiwaki-Dantas

M.C

., et al. Antibacterial activity of anesthetic solutions and preservatives: an in vitro comparative study. Cornea. 19:353–354, 2000.

25.

Hesje

C.K

., Borsos

S.D

., and Blondeau

J.M

. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains. J. Ocul. Pharmacol. Ther. 25:329–334, 2009.

26.

Romanowski,

E.G.

, Mah,

F.S.

, Yates,

K.A.

, et al. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model. Am. J. Ophthalmol. 139:867–877, 2005.

27.

Tungsiripat,

., Sarayba

M.A

., Kaufman

M.B

., et al. Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. Am. J. Ophthalmol. 136:76–81, 2003.